research:concordance_with_aad_guidelines_for_the_treatment_of_acne_vulgaris
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
research:concordance_with_aad_guidelines_for_the_treatment_of_acne_vulgaris [2016/09/20 22:05] schillil [Forum Discussion Thread] |
research:concordance_with_aad_guidelines_for_the_treatment_of_acne_vulgaris [2020/04/29 21:09] (current) crundle |
||
|---|---|---|---|
| Line 1: | Line 1: | ||
| - | ====== Concordance with AAD guidelines for the treatment of acne vulgaris====== | + | =====Characterization of Oral Antibiotics for Acne Treatment====== |
| - | **Objective:** //The objective of this study is to evaluate physician concordance with AAD guidelines for the treatment of acne vulgaris.// | + | **Objective:** |
| + | Aim 1: Characterize the international distribution of oral antibiotic use for acne in the pediatric and young adult population ages 12 to 20. | ||
| + | Aim 2: Characterize the international distribution of oral antibiotic use for acne in the adult population ages 21 to 40. | ||
| - | **Rationale:** //The American Academy of Dermatology (AAD) has published guidelines for the use of systemic antibiotics for the management of acne. These include: 1) minimizing the duration of therapy (ideally to 3-4 months and no longer than 6 months) to decrease risk of resistance and 2) prescribing concomitant treatment with a topical retinoid or topical retinoid/benzoyl peroxide to increase efficacy. A large retrospective cohort study of teenagers in the United Kingdom revealed that of antibiotic courses prescribed by general practitioners, 29% exceeded 6 months in duration, and 62% were not associated with a topical retinoid. Our study aims to determine adherence with AAD guidelines for oral antibiotic use in the management of patients with acne among general practitioners and dermatologists in the United States and other countries. The evidence through the OHDSI network may help identify a need to improve concordance to achieve the best treatment efficacy for patients.// | + | //**Rationale:** // |
| + | Acne is a common and disabling medical condition, particularly amongst adolescents and young adults.[1] According to the Global Burden of Disease Study 2016, acne is the most disabling skin condition worldwide, responsible for 0.28% of global burden from all diseases.[2] In addition to physical disfigurement, the profound psychosocial effects of acne have been recognized for over half a century.[3] Guidelines established by the American Academy of Dermatology recommend minimizing the duration of systemic antibiotics for the management of acne ideally to 3-4 months and no longer than 6 months in order to decrease risk of resistance.[1] A recent systematic review demonstrated that over 50% of P. acnes strains are reported as resistant in all major regions of the world.[4] In addition to promoting resistance, long-term oral antibiotic use has been associated with a number of adverse events including microbiome disruption and pharyngitis, as well as possible associations with inflammatory bowel disease and obesity.[5] Despite these adverse effects, oral antibiotics are often prescribed for acne for longer durations than acne guidelines recommend.[5] A large retrospective cohort study of teenagers in the UK revealed that 29% of antibiotic courses prescribed by general practitioners exceeded 6 months in duration.[5] A similar retrospective cohort study of teenagers and young adults in the US found that 18% of antibiotic courses exceeded 6 months.[6] Our study will investigate oral antibiotic use for acne over the last ten years across the globe in both pediatric/young adult and adult populations. OHDSI network evidence will identify areas of the globe most in need of improving guideline concordance//.// | ||
| - | **Project Lead(s):** //Stephanie Chapman, Renee Domozych, Jessica Mounessa, Robert P. Dellavalle, Lisa Schilling// | + | **Project Lead(s):** //Robert P. Dellavalle, Lisa M. Schilling// |
| - | + | ||
| - | Please provide any comments or suggestions. | + | |
| - | ===== Forum Discussion Thread ===== | + | **Coordinating Institution(s):** //University of Colorado School of Medicine// |
| - | [[http://forums.ohdsi.org/t/ohdsi-study-concordance-with-antibiotic-treatment-guidelines-for-acne/1703]]// | + | |
| + | **Additional Participants:** // //Chante Karimkhani: ck2525@caa.columbia.edu | ||
| + | Chandler Rundle: chandler.rundle@gmail.com | ||
| + | Megan Branda: MEGAN.BRANDA@cuanschutz.edu | ||
| + | John Barbieri: john.barbieri@uphs.upenn.edu | ||
| + | Chris Knoll: cknoll1@its.jnj.com | ||
| + | David Margolis: margo@mail.med.upenn.edu | ||
| + | Patrick Ryan: ryan@ohdsi.org | ||
| + | Martijn Schuemie: m.schuemie@erasmusmc.nl | ||
| + | Jonathan Silverberg: JonathanISilverberg@gmail.com | ||
| + | Dylan Ray: DYLAN.RAY@cuanschutz.edu | ||
| + | Sara Deakyne: Sara.DeakyneDavies@childrenscolorado.org | ||
| + | |||
| + | **Full Draft Protocol:** //Please provide any comments or suggestions.// | ||
| + | [[https://docs.google.com/document/d/1LnugUQrloOn-3cZJDdTpgVYEsynu7SBztFtjzjAuEDE/edit]] | ||
| + | |||
| + | **Initial Proposal Date:** //25 August 2016// | ||
| + | |||
| + | **Launch Date:** // // | ||
| + | |||
| + | **Study Closure Date:** // // | ||
| + | |||
| + | **Forum Discussion Thread** | ||
| + | |||
| + | http://forums.ohdsi.org/t/ohdsi-study-concordance-with-antibiotic-treatment-guidelines-for-acne/1703 | ||
research/concordance_with_aad_guidelines_for_the_treatment_of_acne_vulgaris.1474409123.txt.gz · Last modified: 2016/09/20 22:05 by schillil
Page Tools
